AstraZeneca boss Pascal Soriot's 'pivotal' year is turning out horribly

Firm’s share price has crashed after a key cancer drug flopped in trials, leading £13m-a-year CEO to insist: ‘I’m not a quitter’This year would be “pivotal” for AstraZeneca, its chief executive, Pascal Soriot, has said for ages. It would mark the moment when the firm would display the new wonders from its laboratories. The march towards annual revenues of $45bn (£34.5bn) by 2023, the target set when Pfizer’s takeover offer was rebuffed three